Imaging and histologic prognostic factors in triple-negative breast cancer and carcinoma in situ as a prognostic factor

Sebastián, Cristina Sebastián; Mur, Carmen García; Ciria, S. Cruz; Rosero, D. S.; Bañeres, Belén Gros

doi:10.1016/j.rxeng.2016.07.003

Cited by 4 publications

(4 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There has yet to be a common consensus between the clinical features and prognostic implications for tumors with concomitant DCIS and IDC. There has been increasing evidence to suggest that women with IDC‐DCIS may present at a younger age with smaller sized tumors with few or no nodal involvement 9,10 . Our results indicated that IDC‐DCIS is associated with smaller sized tumors and a lower overall clinical stage, thereby concurring with the hypothesis that tumors with concomitant DCIS were less biologically aggressive.…”

Section: Discussionsupporting

confidence: 86%

“…There has been increasing evidence to suggest that women with IDC‐DCIS may present at a younger age with smaller sized tumors with few or no nodal involvement. 9 , 10 Our results indicated that IDC‐DCIS is associated with smaller sized tumors and a lower overall clinical stage, thereby concurring with the hypothesis that tumors with concomitant DCIS were less biologically aggressive. Likewise, some studies have shown that tumors with concomitant DCIS are likely to express ER, PR, and cerB2 positivity as compared to tumors with No‐DCIS.…”

Section: Discussionsupporting

confidence: 85%

“… 7 , 8 To date, only a handful of Western studies were able to recognize this association where the presence of concomitant in situ disease possibly led to better prognostic features and clinical outcomes. 9 , 10 On the other hand, the role of DCIS in invasive mammary cancer and its clinical significance among the Asian population remains understudied.…”

Section: Discussionmentioning

confidence: 99%

“…The current understanding is that these mammary tumors undergo cellular differentiation from the in situ form of disease into the invasive phenotype and this slow progression may suggest a possible favorable clinical prognosis 7,8 . To date, only a handful of Western studies were able to recognize this association where the presence of concomitant in situ disease possibly led to better prognostic features and clinical outcomes 9,10 . On the other hand, the role of DCIS in invasive mammary cancer and its clinical significance among the Asian population remains understudied.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Does concomitant ductal carcinoma in situ affect the clinical outcome in breast cancer patients with invasive ductal carcinoma: An Asian perspective

et al. 2022

View full text Add to dashboard Cite

Background Ductal carcinoma in situ (DCIS) is an established precursor to invasive ductal carcinoma (IDC) and its coexistence with IDC appear to favor reduced biological aggressiveness. Its prognostic implication and ability to affect clinical outcome has been understudied in Asia. This study aims to explore if concomitant DCIS affects the clinical behavior and outcomes among Asians. Aim Stages I to III breast cancer patients with histological proven IDC, diagnosed and treated in a single institution from June 1, 2004 to June 30, 2014 were included in this study. Statistical analyses were conducted using Χ 2 test, independent t test, multivariate logistic regression and Kaplan–Meier test. Methods and Results A total of 818 patients were identified, including 224 and 594 patients with isolated IDC (No‐DCIS) and IDC with coexisting DCIS (IDC‐DCIS) respectively. Patients with IDC‐DCIS were found to have smaller tumors (median: 22 mm, p ≤ .01), estrogen receptor positivity ( p = .001), progesterone receptor positivity ( p < .001) and associated with better pathological stage ( p = .001). Patients with No‐DCIS were 1.6 times more likely to develop disease progression (95% CI: 1.1–2.3, p = .027) and subsequently associated with distant recurrences (20.5% vs. 13.6%, p = .02). The breast cancer specific 5 year overall survival rate for patients with No‐DCIS and those with IDC‐DCIS was 90.9% (95% CI: 86.2%–94.5%) and 93.7% (95% CI: 91.4%–95.5%), respectively ( p = .202). Conclusion The presence of DCIS component in IDC among Asians is associated with favorable tumor biological profile, thereby indicating reduced disease aggressiveness. Our study is the first to report the clinical significance in terms of disease progression and distant recurrences among Asians.

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Discussionsupporting

confidence: 85%